DrugPatentWatch Database Preview
TRI-LUMA Drug Profile
Which patents cover Tri-luma, and what generic alternatives are available?
Tri-luma is a drug marketed by Galderma Labs Lp and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-nine patent family members in eighteen countries.
The generic ingredient in TRI-LUMA is fluocinolone acetonide; hydroquinone; tretinoin. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fluocinolone acetonide; hydroquinone; tretinoin profile page.
Summary for TRI-LUMA
| International Patents: | 29 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 37 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRI-LUMA |
| DailyMed Link: | TRI-LUMA at DailyMed |
Generic Entry Opportunity Date for TRI-LUMA
Generic Entry Date for TRI-LUMA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CREAM;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TRI-LUMA
| Drug Class | Corticosteroid Melanin Synthesis Inhibitor Retinoid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists Melanin Synthesis Inhibitors |
| Physiological Effect | Depigmenting Activity |
US Patents and Regulatory Information for TRI-LUMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galderma Labs Lp | TRI-LUMA | fluocinolone acetonide; hydroquinone; tretinoin | CREAM;TOPICAL | 021112-001 | Jan 18, 2002 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Galderma Labs Lp | TRI-LUMA | fluocinolone acetonide; hydroquinone; tretinoin | CREAM;TOPICAL | 021112-001 | Jan 18, 2002 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Galderma Labs Lp | TRI-LUMA | fluocinolone acetonide; hydroquinone; tretinoin | CREAM;TOPICAL | 021112-001 | Jan 18, 2002 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Galderma Labs Lp | TRI-LUMA | fluocinolone acetonide; hydroquinone; tretinoin | CREAM;TOPICAL | 021112-001 | Jan 18, 2002 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TRI-LUMA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2005115856 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004037201 | Start Trial |
| South Korea | 20060040755 | Start Trial |
| Japan | 2010280738 | Start Trial |
| Denmark | 1562531 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
